RICHMOND, Calif., April 4, 2019 /PRNewswire/ -- Sangamo
Therapeutics, Inc. (Nasdaq: SGMO) today announced the pricing of an
underwritten public offering of 11,000,000 shares of its common
stock at a price to the public of $11.50 per share. All of the shares are being
sold by Sangamo. The gross proceeds to Sangamo from the offering,
before deducting the underwriting discounts and commissions and
offering expenses, are expected to be approximately $126.5 million. The offering is expected to close
on or about April 8, 2019, subject to
customary closing conditions. In addition, Sangamo has granted the
underwriters of the offering a 30-day option to purchase up to an
additional 1,650,000 shares of its common stock at the public
offering price, less the underwriting discounts and
commissions.
Sangamo anticipates using the net proceeds from the offering for
working capital and other general corporate purposes, including
support for its own and its partnered gene therapy, genome editing,
cell therapy and gene regulation product candidates and research
programs, its manufacturing facilities and other business
development activities.
Cowen and Company, LLC, Wells Fargo Securities, LLC and Barclays
Capital Inc. are acting as joint book-running managers for the
offering.
A registration statement relating to the shares was previously
filed with and became effective by rule of the Securities and
Exchange Commission. The offering is being made solely by means of
a prospectus. A final prospectus supplement and accompanying
prospectus relating to the offering will be filed with the
Securities and Exchange Commission and will be available on the
Securities and Exchange Commission's website located at
http://www.sec.gov. A copy of the final prospectus supplement
and accompanying prospectus relating to the offering, when
available, may be obtained from Cowen and Company, LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, or by
telephone at (631) 274-2806; or from Wells Fargo Securities, LLC,
Attention: Equity Syndicate Department, 375 Park Avenue,
New York, New York 10152, or by
telephone at (800) 326-5897 or email to
cmclientsupport@wellsfargo.com; or from Barclays Capital Inc., c/o
Broadridge Financial Solutions, Attn: Prospectus Department, 1155
Long Island Avenue, Edgewood, NY
11717, or by telephone at (888) 603-5847, or by email at
barclaysprospectus@broadridge.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating
ground-breaking science into genomic medicines with the potential
to transform patients' lives using gene therapy, ex-vivo
gene-edited cell therapy, in vivo genome editing, and gene
regulation.
Forward Looking Statements
This press release contains forward-looking statements regarding
Sangamo's current expectations. These forward-looking statements
include, without limitation, references to Sangamo's expectations
regarding the closing of the public offering and its anticipated
use of net proceeds from the offering. These statements are not
guarantees of future performance and are subject to certain risks,
uncertainties and assumptions that are difficult to predict.
Factors that could cause actual results to differ include, but are
not limited to, risks and uncertainties related to the satisfaction
of customary closing conditions related to the public offering, or
factors that result in changes to the Company's anticipated use of
proceeds. These and other risks and uncertainties are described
more fully in the section captioned "Risk Factors" in the final
prospectus supplement related to the public offering to be filed
with the Securities and Exchange Commission as well as Sangamo's
Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities
and Exchange Commission on March 1,
2019. Forward-looking statements contained in this
announcement are made as of this date, and Sangamo undertakes no
duty to update such information except as required under applicable
law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/sangamo-therapeutics-announces-pricing-of-public-offering-of-common-stock-300824526.html
SOURCE Sangamo Therapeutics, Inc.